About: Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug–Drug Interactions Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug–Drug Interactions
Creator	Hesselink, Dennis Lemaitre, Florian Dirk, ║ Elens, Laure Langman, Loralie Moes, Jan Molinaro, Mariadelfina Stein Bergan, ¶ Venkataramanan, Raman
Source	Medline; PMC
abstract	COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-coronavirus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy. Solid organ transplant recipients are perceived to be at increased risk of severe COVID-19 because of their immunosuppressed conditions due to chronic use of immunosuppressive drugs (ISDs). It is therefore likely that solid organ transplant recipients will be treated with these experimental antivirals. METHODS: This article is not intended to provide a systematic literature review on investigational treatments tested against COVID-19; rather, the authors aim to provide recommendations for therapeutic drug monitoring of ISDs in transplant recipients infected with SARS-CoV-2 based on a review of existing data in the literature. RESULTS: Management of drug–drug interactions between investigational anti-SARS-CoV-2 drugs and immunosuppressants is a complex task for the clinician. Adequate immunosuppression is necessary to prevent graft rejection while, if critically ill, the patient may benefit from pharmacotherapeutic interventions directed at limiting SARS-CoV-2 viral replication. Maintaining ISD concentrations within the desired therapeutic range requires a highly individualized approach that is complicated by the pandemic context and lack of hindsight. CONCLUSIONS: With this article, the authors inform the clinician about the potential interactions of experimental COVID-19 treatments with ISDs used in transplantation. Recommendations regarding therapeutic drug monitoring and dose adjustments in the context of COVID-19 are provided.
has issue date	2020-04-23(xsd:dateTime)
bibo:doi	10.1097/ftd.0000000000000761
bibo:pmid	32304488
has license	no-cc
sha1sum (hex)	3311f6ac7a2115167140dc003f08b75111190eab
schema:url	https://doi.org/10.1097/ftd.0000000000000761
resource representing a document's title	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug–Drug Interactions
has PubMed Central identifier	PMC7188032
has PubMed identifier	32304488
schema:publication	Ther Drug Monit
resource representing a document's body	covid:3311f6ac7a2115167140dc003f08b75111190eab#body_text
is schema:about of	named entity 'Drug' named entity 'Transplant' named entity 'Therapeutic Drug Monitoring' named entity 'SARS-CoV-2' named entity 'loading dose' named entity 'chloroquine' named entity 'COVID' named entity 'SARS-CoV-1' named entity 'immunosuppressed' named entity 'Glucocorticoid' named entity 'CsA' named entity 'pharmacotherapeutic' named entity 'hepatic' named entity 'CYP' named entity 'chloroquine' named entity 'RNA chains' named entity 'hepatic' named entity 'infection' named entity 'EC50' named entity 'hemoglobin' named entity 'glucuronidation' named entity 'enzyme activity' named entity 'lung disease' named entity 'liver transplant' named entity 'OATP1B1' named entity 'OATP1B3' named entity '30 hours' named entity 'critical care' named entity 'enzyme' named entity 'kidney' named entity 'Pgp' named entity 'ventricular arrhythmias' named entity 'metabolized' named entity 'hepatic' named entity 'infection' named entity 'CsA' named entity 'tocilizumab' named entity 'cardiac transplant' named entity 'DDIs' named entity 'CYP450' named entity 'IgG1k' named entity 'OATP1B3' named entity 'selectively inhibiting' named entity 'Foster City' named entity 'heme' named entity 'HIV' named entity 'drug therapy' named entity 'COVID-19' named entity 'ISDs' named entity 'cardiac toxicity' named entity 'biochemical' named entity 'IFN' named entity 'TDM' named entity 'dizziness' named entity 'COVID-19' named entity 'half-life' named entity 'hyperinflammation' named entity 'Hydroxychloroquine' named entity 'EC50' named entity 'favipiravir' named entity 'saquinavir' named entity 'CYP3A4' named entity 'posology' named entity 'proper dose' named entity 'competitive inhibition' named entity 'COVID' named entity 'half-life' named entity 'alkylated' named entity 'tocilizumab' named entity 'COVID' named entity 'COVID-19' named entity 'serum albumin' named entity 'quarantine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software